| Year |
Citation |
Score |
| 2022 |
Sugita M, Galetto R, Zong H, Ewing-Crystal N, Trujillo-Alonso V, Mencia-Trinchant N, Yip W, Filipe S, Lebuhotel C, Gouble A, Hassane DC, Smith J, Roboz GJ, Guzman ML. Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia. Nature Communications. 13: 2227. PMID 35484102 DOI: 10.1038/s41467-022-29668-9 |
0.339 |
|
| 2021 |
Balandrán JC, Dávila-Velderrain J, Sandoval-Cabrera A, Zamora-Herrera G, Terán-Cerqueda V, García-Stivalet LA, Limón-Flores JA, Armenta-Castro E, Rodríguez-Martínez A, Leon-Chavez BA, Vallejo-Ruiz V, Hassane DC, Pérez-Tapia SM, Ortiz-Navarrete V, Guzman ML, et al. Patient-Derived Bone Marrow Spheroids Reveal Leukemia-Initiating Cells Supported by Mesenchymal Hypoxic Niches in Pediatric B-ALL. Frontiers in Immunology. 12: 746492. PMID 34737747 DOI: 10.3389/fimmu.2021.746492 |
0.32 |
|
| 2021 |
Sugita M, Wilkes DC, Bareja R, Eng KW, Nataraj S, Jimenez-Flores RA, Yan L, De Leon JP, Croyle JA, Kaner J, Merugu S, Sharma S, MacDonald TY, Noorzad Z, Panchal P, ... ... Hassane DC, et al. Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. Npj Precision Oncology. 5: 44. PMID 34040147 DOI: 10.1038/s41698-021-00183-2 |
0.304 |
|
| 2019 |
Bystrom LM, Bezerra DP, Hsu HT, Zong H, Lara-Martínez LA, De Leon JP, Emmanuel M, Méry D, Gardenghi S, Hassane D, Neto CC, Cunningham-Rundles S, Becker MW, Rivella S, Guzman ML. Cranberry A-type proanthocyanidins selectively target acute myeloid leukemia cells. Blood Advances. 3: 3261-3265. PMID 31698457 DOI: 10.1182/Bloodadvances.2018026633 |
0.463 |
|
| 2019 |
Desai P, Hassane D, Roboz GJ. Clonal Hematopoiesis and risk of Acute Myeloid Leukemia. Best Practice & Research. Clinical Haematology. 32: 177-185. PMID 31203999 DOI: 10.1016/J.Beha.2019.05.007 |
0.343 |
|
| 2018 |
Roboz GJ, Mandrekar SJ, Desai P, Laumann K, Walker AR, Wang ES, Kolitz JE, Powell BL, Attar EC, Stock W, Bloomfield CD, Kohlschmidt J, Mrózek K, Hassane DC, Garraway L, et al. Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Advances. 2: 3608-3617. PMID 30567725 DOI: 10.1182/Bloodadvances.2018023689 |
0.326 |
|
| 2018 |
Desai P, Mencia-Trinchant N, Savenkov O, Simon MS, Cheang G, Lee S, Samuel M, Ritchie EK, Guzman ML, Ballman KV, Roboz GJ, Hassane DC. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nature Medicine. 24: 1015-1023. PMID 29988143 DOI: 10.1038/S41591-018-0081-Z |
0.349 |
|
| 2018 |
Roboz GJ, Ritchie EK, Dault Y, Lam L, Marshall DC, Cruz NM, Hsu HC, Hassane DC, Christos PJ, Ippoliti C, Scandura JM, Guzman ML. Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia. Haematologica. PMID 29724902 DOI: 10.3324/Haematol.2017.183418 |
0.39 |
|
| 2018 |
Roboz GJ, Sugita M, Mosquera JM, Wilkes DC, Nataraj S, Jimenez-Flores RA, Bareja R, Yan L, Eng KW, Croyle JA, MacDonald TY, Noorzad Z, Pancirer D, Cheng S, Xiang JZ, ... ... Hassane DC, et al. Targeting the Epichaperome As an Effective Precision Medicine Approach in a Novel PML-SYK Fusion Acute Myeloid Leukemia Blood. 132: 1435-1435. DOI: 10.1182/Blood-2018-99-118764 |
0.444 |
|
| 2018 |
Kaner JD, Mencia-Trinchant N, Schaap A, Roboz GJ, Lee S, Desai P, Samuel M, Krichevsky S, Udoyen I, Hassane DC, Guzman ML, Ritchie EK. Acute Myeloid Leukemia (AML) with Somatic Mutations in PTPN11 Is Associated with Treatment Resistance and Poor Overall Survival Blood. 132: 2760-2760. DOI: 10.1182/Blood-2018-99-110319 |
0.344 |
|
| 2018 |
Sugita M, Mencia-Trinchant N, Ewing-Crystal N, Suppa G, Galetto R, Gouble A, Smith J, Roboz GJ, Hassane DC, Guzman ML. Abstract 5681: Prediction of immunotherapy outcome by multimodal assessment of minimal residual disease and persistence of allogeneic anti-CD123 CAR T-cells (UCART123) in pre-clinical models of acute myeloid leukemia Cancer Research. 78: 5681-5681. DOI: 10.1158/1538-7445.Am2018-5681 |
0.407 |
|
| 2017 |
Poran A, Nötzel C, Aly O, Mencia-Trinchant N, Harris CT, Guzman ML, Hassane DC, Elemento O, Kafsack BFC. Single-cell RNA sequencing reveals a signature of sexual commitment in malaria parasites. Nature. 551: 95-99. PMID 29094698 DOI: 10.1038/Nature24280 |
0.313 |
|
| 2017 |
Margolskee E, Hasserjian RP, Hassane D, Tam W, Mathew S, Ok CY, Wang SA, Oak J, Arber DA, Orazi A. Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis. American Journal of Clinical Pathology. 148: 49-57. PMID 28927162 DOI: 10.1093/Ajcp/Aqx043 |
0.311 |
|
| 2017 |
Allan JN, Roboz GJ, Askin G, Ritchie E, Scandura J, Christos P, Hassane DC, Guzman ML. CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine. Leukemia & Lymphoma. 1-8. PMID 28718760 DOI: 10.1080/10428194.2017.1352089 |
0.305 |
|
| 2017 |
Geyer JT, Tam W, Liu YC, Chen Z, Wang SA, Bueso-Ramos C, Oak J, Arber DA, Hsi E, Rogers HJ, Levinson K, Bagg A, Hassane DC, Hasserjian RP, Orazi A. Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 28548124 DOI: 10.1038/Modpathol.2017.45 |
0.327 |
|
| 2017 |
Mencia-Trinchant N, Hu Y, Alas MA, Ali F, Wouters BJ, Lee S, Ritchie EK, Desai P, Guzman ML, Roboz GJ, Hassane DC. Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations. The Journal of Molecular Diagnostics : Jmd. PMID 28525762 DOI: 10.1016/J.Jmoldx.2017.03.005 |
0.363 |
|
| 2017 |
Nayar U, Sadek J, Reichel J, Hernandez-Hopkins D, Akar G, Barelli PJ, Sahai MA, Zhou H, Totonchy J, Jayabalan D, Niesvizky R, Guasparri I, Hassane D, Liu Y, Sei S, et al. Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies. The Journal of Clinical Investigation. PMID 28504647 DOI: 10.1172/Jci83936 |
0.436 |
|
| 2017 |
Cruz NM, Mencia-Trinchant N, Hassane DC, Guzman ML. Minimal residual disease in acute myelogenous leukemia. International Journal of Laboratory Hematology. 39: 53-60. PMID 28447422 DOI: 10.1111/Ijlh.12670 |
0.365 |
|
| 2017 |
Glass J, Hassane DC, Wouters B, Kunimoto H, Avellino R, Garrett-Bakelman FE, Guryanova OA, Bowman R, Redlich S, Intlekofer A, Meydan C, Qin T, Fall MP, Alonso A, Guzman ML, et al. Epigenetic Identity in AML Depends on Disruption of Non-promoter Regulatory Elements and is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. Cancer Discovery. PMID 28408400 DOI: 10.1158/2159-8290.Cd-16-1032 |
0.334 |
|
| 2017 |
Desai P, Mencia-Trinchant N, Oleksandr S, Simon MS, Lee S, Ritchie EK, Guzman ML, Ballman K, Roboz GJ, Hassane DC. Acute Myeloid Leukemia (AML) Patients Demonstrate Increased Prevalence of AML-Defining Mutations in Peripheral Blood Years Prior to the Development of Overt Leukemia: A Case-Control Study Blood. 130: 408-408. DOI: 10.1182/Blood.V130.Suppl_1.408.408 |
0.348 |
|
| 2016 |
Li S, Garrett-Bakelman FE, Chung SS, Sanders MA, Hricik T, Rapaport F, Patel J, Dillon R, Vijay P, Brown AL, Perl AE, Cannon J, Bullinger L, Luger S, Becker M, ... ... Hassane DC, et al. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nature Medicine. PMID 27322744 DOI: 10.1038/Nm.4125 |
0.371 |
|
| 2016 |
Silver RT, Barel A, Lascu E, Ritchie EK, Roboz GJ, Christos P, Orazi A, Hassane DC, Tam W, Cross NCP. The Effect of Initial Molecular Profile on Response to Recombinant Interferon Alpha (rIFNα) Treatment in Early Myelofibrosis Blood. 128: 944-944. DOI: 10.1182/Blood.V128.22.944.944 |
0.323 |
|
| 2016 |
Guzman ML, Sugita M, Zong H, Ewing-Crystal N, Trujillo-Alonso V, Mencia-Trinchant N, Lam L, Cruz NM, Galetto R, Gouble A, Hassane DC, Smith J, Roboz GJ. Allogeneic Tcrα/β Deficient CAR T-Cells Targeting CD123 Prolong Overall Survival of AML Patient-Derived Xenografts Blood. 128: 765-765. DOI: 10.1182/Blood.V128.22.765.765 |
0.451 |
|
| 2016 |
Lee S, Barnard J, DeZern AE, Maciejewski JP, Alali N, Steensma DP, Ritchie EK, Desai P, Garcia-Manero G, Ali F, Rizzo N, Hassane DC, Komrokji RS, Sekeres MA, Roboz GJ. Is Serial Monitoring of Myeloid Mutations Clinically Relevant in Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (CRC) Blood. 128: 297-297. DOI: 10.1182/Blood.V128.22.297.297 |
0.344 |
|
| 2016 |
Mencia-Trinchant N, Youssef A, Hu Y, Ali F, Ritchie EK, Guzman ML, Roboz GJ, Hassane DC. Minimal Residual Disease Assessment of Common and Rare NPM1 Mutations Using a Single Massively Multiplex Digital PCR Assay Blood. 128: 2888-2888. DOI: 10.1182/Blood.V128.22.2888.2888 |
0.36 |
|
| 2016 |
Li S, Garrett-Bakelman FE, Chung SS, Hricik T, Rapaport F, Patel J, Dillon R, Vijay P, Brown AL, Perl AE, Connon J, Sanders MA, Valk PJM, Bullinger L, Luger S, ... ... Hassane DC, et al. Abstract LB-073: Epigenome evolution in relapsed acute myeloid leukemia Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-073 |
0.316 |
|
| 2015 |
Garrett-Bakelman FE, Li S, Chung SS, Hricik T, Franck R, Patel J, Dillon R, Vijay P, Brown AL, Perl AE, Cannon BJ, Sanders MA, Valk PJM, Bullinger L, Luger S, ... ... Hassane DC, et al. Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia Blood. 126: 306-306. DOI: 10.1182/Blood.V126.23.306.306 |
0.398 |
|
| 2014 |
Guzman ML, Yang N, Sharma KK, Balys M, Corbett CA, Jordan CT, Becker MW, Steidl U, Abdel-Wahab O, Levine RL, Marcucci G, Roboz GJ, Hassane DC. Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. Molecular Cancer Therapeutics. 13: 1979-90. PMID 24934933 DOI: 10.1158/1535-7163.Mct-13-0963 |
0.435 |
|
| 2014 |
Mencia-Trinchant N, Roboz GJ, Carroll MP, Guzman ML, Hassane DC. Ultra-Deep Sequencing Defines Stem Cell-Specific Diversity Patterns in Acute Myelogenous Leukemia Blood. 124: 4790-4790. DOI: 10.1182/Blood.V124.21.4790.4790 |
0.434 |
|
| 2014 |
Allan JN, Jayabalan D, Niesvizky R, Mark TM, Pearse R, Rossi AC, Tegnestam L, Hassane DC, Guzman ML. Proteasome Inhibitor Treatment in Multiple Myeloma Can Mobilize Hematopoietic Stem Cells in the Absence of G-CSF Blood. 124: 2452-2452. DOI: 10.1182/Blood.V124.21.2452.2452 |
0.32 |
|
| 2014 |
Allan JN, Roboz GJ, Feldman EJ, Scandura JM, Ritchie EK, Lam L, Xie W, Hsu H, Hassane DC, Guzman ML. Interleukin 2 Receptor-α (CD25) Expression Is Associated with Shortened Overall Survival and Resistance to Induction Therapy with Plerixafor and Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Blood. 124: 1041-1041. DOI: 10.1182/Blood.V124.21.1041.1041 |
0.301 |
|
| 2014 |
Kita K, Tran A, Brown LM, Hassane DC, Carey S, Matov A, Reinhart-King CA, Giannakakou P. Abstract 1158: Microtubule perturbation regulates remodeling of tumor microenvironment by modulating the composition of tumor cell secretome Cancer Research. 74: 1158-1158. DOI: 10.1158/1538-7445.Am2014-1158 |
0.376 |
|
| 2013 |
Sen S, Hassane DC, Corbett C, Becker MW, Jordan CT, Guzman ML. Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity. Experimental Hematology. 41: 799-807.e4. PMID 23660068 DOI: 10.1016/J.Exphem.2013.04.012 |
0.338 |
|
| 2013 |
Sampson ER, McMurray HR, Hassane DC, Newman L, Salzman P, Jordan CT, Land H. Gene signature critical to cancer phenotype as a paradigm for anticancer drug discovery. Oncogene. 32: 3809-18. PMID 22964631 DOI: 10.1038/Onc.2012.389 |
0.341 |
|
| 2013 |
Felipe Rico J, Hassane DC, Guzman ML. Acute myelogenous leukemia stem cells: from Bench to Bedside. Cancer Letters. 338: 4-9. PMID 22713929 DOI: 10.1016/J.Canlet.2012.05.034 |
0.43 |
|
| 2013 |
Galletti G, Cleveland K, Matov A, Hayes JE, Klein RJ, Hassane DC, Nicacio LV, Giannakakou P, Shah MA. Clinical and preclinical evaluation of taxane sensitivity in gastric cancer (GC): Relevance of GC histology. Journal of Clinical Oncology. 31: 37-37. DOI: 10.1200/Jco.2013.31.4_Suppl.37 |
0.307 |
|
| 2013 |
Tran A, Kita K, Matov A, Hassane DC, Brown LM, Giannakakou P. Abstract 5162: Microtubule stabilization alters tumor secretome and fibroblast activation. Cancer Research. 73: 5162-5162. DOI: 10.1158/1538-7445.Am2013-5162 |
0.372 |
|
| 2013 |
Carbonaro M, Hassane D, Giannakakou P. Abstract 2318: The microtubule cytoskeleton in the dynamic regulation of translation: implications for taxane therapy. Cancer Research. 73: 2318-2318. DOI: 10.1158/1538-7445.Am2013-2318 |
0.334 |
|
| 2012 |
Ashton JM, Balys M, Neering SJ, Hassane DC, Cowley G, Root DE, Miller PG, Ebert BL, McMurray HR, Land H, Jordan CT. Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells. Cell Stem Cell. 11: 359-72. PMID 22863534 DOI: 10.1016/J.Stem.2012.05.024 |
0.424 |
|
| 2012 |
Guasparri I, Hassane DC, Roshal M, Cesarman E. The Viral Oncoprotein vFLIP Encoded by KSHV/HHV-8 Is Responsible for the Unique Transcriptional Signature and Phenotypic Features of Primary Effusion Lymphoma Blood. 120: 900-900. DOI: 10.1182/Blood.V120.21.900.900 |
0.401 |
|
| 2012 |
Bystrom L, Hsu H, Neto C, Roboz GJ, Hassane DC, Rivella S, Guzman ML. A-Type Proanthocyanidins From Cranberries Target Acute Myelogenous Leukemia Stem Cells. Blood. 120: 2986-2986. DOI: 10.1182/Blood.V120.21.2986.2986 |
0.453 |
|
| 2012 |
Tran AD, Brown LM, Hassane DC, Giannakakou P. Abstract 1502: Microtubule stabilization alters tumor secretome and fibroblast activation Cancer Research. 72: 1502-1502. DOI: 10.1158/1538-7445.Am2012-1502 |
0.371 |
|
| 2011 |
Ashton JM, Balys M, Neering S, Cowley G, Root DE, Miller PG, Ebert B, McMurray H, Hassane DC, Land H, Jordan CT. Oncogene Cooperativity Analysis Reveals a Novel Set of Genes That Regulate the In Vivo Growth and Survival of Leukemia Stem Cells Blood. 118: 553-553. DOI: 10.1182/Blood.V118.21.553.553 |
0.449 |
|
| 2011 |
Hassane DC, Leon JPD, Corbett C, Rossi RM, Xie W, Jordan CT, Guzman ML. Troglitazone and Prochloroperazine Repositioned As An Anti-Leukemia Stem Cell Drug Combination Using Chemical Genomics-Based Prediction Blood. 118: 1885-1885. DOI: 10.1182/Blood.V118.21.1885.1885 |
0.359 |
|
| 2011 |
Xie W, Hassane DC, Jordan CT, Roboz GJ, Guzman ML. High Throughput Screening Reveals Unique Sensitivity of CD34+CD38- AML Cells to Isotretinoin and Tretinoin Blood. 118: 1430-1430. DOI: 10.1182/Blood.V118.21.1430.1430 |
0.371 |
|
| 2011 |
Sharma KK, Rico JF, Hassane DC, Chiosis G, Guzman ML. Dysregulated Expression of HSP70 Isoforms in Acute Myelogenous Leukemia (AML) Blood. 118: 1370-1370. DOI: 10.1182/Blood.V118.21.1370.1370 |
0.393 |
|
| 2011 |
Yang N, Hassane DC, Balys M, Corbett CA, Jordan CT, Guzman ML. Abstract 2145: AR-42, a novel histone deacetylase inhibitor with selectivity against leukemia stem cell via apoptosis induction, inhibition of chaperone function of heat shock protein 90 in acute myeloid leukemia Cancer Research. 71: 2145-2145. DOI: 10.1158/1538-7445.Am2011-2145 |
0.43 |
|
| 2010 |
Hassane DC, Sen S, Minhajuddin M, Rossi RM, Corbett CA, Balys M, Wei L, Crooks PA, Guzman ML, Jordan CT. Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood. 116: 5983-90. PMID 20889920 DOI: 10.1182/Blood-2010-04-278044 |
0.397 |
|
| 2009 |
Hassane D, Sen S, Corbett CA, Balys M, Rossi RM, Crooks PA, Guzman ML, Jordan CT. Chemical Genomic Screening Reveals That PI3K/mTOR Inhibition Enhances Activity of the Anti-Leukemia Stem Cell Compound Parthenolide. Blood. 114: 388-388. DOI: 10.1182/Blood.V114.22.388.388 |
0.455 |
|
| 2009 |
Ashton JM, Hassane D, Neering S, Bushnell TP, Jordan CT. Synergistically Regulated Genes and Pathways in Leukemias Induced by Co-Expression of BCR-ABL and Nup98-HoxA9. Blood. 114: 3473-3473. DOI: 10.1182/Blood.V114.22.3473.3473 |
0.464 |
|
| 2009 |
Hassane D, Balys M, Marcucci G, Byrd JC, Jordan CT, Guzman ML. Identification of the Histone Deacetylase Inhibitor (HDACi), AR-42, as a Novel Anti-Leukemia Stem Cell Agent in Acute Myeloid Leukemia (AML). Blood. 114: 2070-2070. DOI: 10.1182/Blood.V114.22.2070.2070 |
0.44 |
|
| 2008 |
Hassane DC, Guzman ML, Corbett C, Li X, Abboud R, Young F, Liesveld JL, Carroll M, Jordan CT. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood. 111: 5654-62. PMID 18305216 DOI: 10.1182/Blood-2007-11-126003 |
0.435 |
|
| 2008 |
Hassane DC, Ashton JM, Guzman ML, Jordan CT. Genes Dysregulated in a Murine Model of Leukemogenesis Comprise a Signature for Identification of Therapeutics in Humans. Blood. 112: 3349-3349. DOI: 10.1182/Blood.V112.11.3349.3349 |
0.342 |
|
| 2007 |
Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennett JM, Sullivan E, Lachowicz JL, Vaughan A, Sweeney CJ, Matthews W, Carroll M, Liesveld JL, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 110: 4427-35. PMID 17804695 DOI: 10.1182/Blood-2007-05-090621 |
0.435 |
|
| 2007 |
Hassane DC, Guzman ML, Corbett C, Li X, Liesveld JL, Young F, Carroll M, Jordan CT. A Search of Public Gene Expression Microarray Data Identifies Novel Agents That Selectively Eradicate AML Stem Cells. Blood. 110: 776-776. DOI: 10.1182/Blood.V110.11.776.776 |
0.437 |
|
| 2006 |
Hassane DC, Guzman ML, Li X, Corbett C, Jordan CT. Molecular Signature for Parthenolide-Induced Apoptosis in AML CD34+ Cells Reveals Targets for Improving Induction of Leukemia-Specific Cell Death. Blood. 108: 2592-2592. DOI: 10.1182/Blood.V108.11.2592.2592 |
0.433 |
|
| 2006 |
Guzman ML, Rossi RM, Li X, Corbett C, Hassane DC, Bushnell T, Carroll M, Sullivan E, Neelakantan S, Crooks PA, Jordan CT. A Novel Orally Available Parthenolide Analog Selectively Eradicates AML Stem and Progenitor Cells. Blood. 108: 237-237. DOI: 10.1182/Blood.V108.11.237.237 |
0.451 |
|
| 2005 |
Guzman ML, Li X, Corbett C, Hassane DC, Jordan CT. Mechanisms Controlling Selective Death of Leukemia Stem Cells in Response to Parthenolide. Blood. 106: 467-467. DOI: 10.1182/Blood.V106.11.467.467 |
0.443 |
|
| 2003 |
Lee RB, Hassane DC, Cottle DL, Pickett CL. Interactions of Campylobacter jejuni cytolethal distending toxin subunits CdtA and CdtC with HeLa cells. Infection and Immunity. 71: 4883-90. PMID 12933829 DOI: 10.1128/Iai.71.9.4883-4890.2003 |
0.582 |
|
| 2003 |
Hassane DC, Lee RB, Pickett CL. Campylobacter jejuni cytolethal distending toxin promotes DNA repair responses in normal human cells. Infection and Immunity. 71: 541-5. PMID 12496208 DOI: 10.1128/Iai.71.1.541-545.2003 |
0.574 |
|
| 2001 |
Hassane DC, Lee RB, Mendenhall MD, Pickett CL. Cytolethal distending toxin demonstrates genotoxic activity in a yeast model. Infection and Immunity. 69: 5752-9. PMID 11500452 DOI: 10.1128/Iai.69.9.5752-5759.2001 |
0.603 |
|
| Show low-probability matches. |